The generic drugmaker’s U.S. unit also must sell the drug line for cholesterol treatment pravastatin.
Source link
Tags: Anti-Competition Issues, biosimilar drugs, C&E Executive News Filter, C&E Industry News Filter, Content Types, corporate, corporate crime, Corporate Crime/Legal Action, Corporate/Industrial News, Crime, Crime/Legal Action, dealing, drug trafficking, Drug Trafficking/Dealing, Factiva Filters, general news, generic, Generic/Biosimilar Drugs, government policy, healthcare, Healthcare/Life Sciences, industrial news, legal action, life sciences, Marketing, Markets, Markets/Marketing, new products, New Products/Services, north america, Pharmaceuticals, political, Political/General News, Price Fixing, prices, product, Product/Service Approvals, products, Products/Services, regulation, Regulation/Government Policy, service approvals, services, smuggling, SYND, TEVA, Teva Pharmaceutical Industries, TEVA.TV, trafficking, Trafficking/Smuggling, United States, WSJ-PRO-WSJ.com
